Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1984 1
1985 2
1987 1
1989 1
1990 2
1991 2
1992 2
1993 1
1994 2
1995 5
1996 2
1997 2
1998 3
1999 3
2000 6
2001 4
2002 6
2003 10
2004 11
2005 15
2006 16
2007 10
2008 21
2009 15
2010 13
2011 18
2012 22
2013 17
2014 21
2015 16
2016 22
2017 12
2018 19
2019 40
2020 27
2021 29
2022 21
2023 23
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Lung Non-Small Cell Carcinoma"
Page 1
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Li BT, et al. N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18. N Engl J Med. 2022. PMID: 34534430 Free PMC article. Clinical Trial.
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conju …
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small …
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing.
Hu J, Zhang L, Xia H, Yan Y, Zhu X, Sun F, Sun L, Li S, Li D, Wang J, Han Y, Zhang J, Bian D, Yu H, Chen Y, Fan P, Ma Q, Jiang G, Wang C, Zhang P. Hu J, et al. Genome Med. 2023 Mar 3;15(1):14. doi: 10.1186/s13073-023-01164-9. Genome Med. 2023. PMID: 36869384 Free PMC article.
METHODS: We characterized the transcriptomes of ~92,000 single cells from 3 pre-treatment and 12 post-treatment patients with non-small cell lung cancer (NSCLC) who received neoadjuvant PD-1 blockade combined with chemotherapy. The 12 post-treatment sa …
METHODS: We characterized the transcriptomes of ~92,000 single cells from 3 pre-treatment and 12 post-treatment patients with non- …
Current Diagnosis and Management of Small-Cell Lung Cancer.
Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Wang S, et al. Mayo Clin Proc. 2019 Aug;94(8):1599-1622. doi: 10.1016/j.mayocp.2019.01.034. Mayo Clin Proc. 2019. PMID: 31378235 Review.
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non-small-cell lung cancer. ...Immunotherapy, including nivolumab with or without ipilimumab, is now av …
Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characterist …
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
LaMarche NM, Hegde S, Park MD, Maier BB, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, Chin T, Reid AM, Reyes-Torres I, Nemeth E, Zhang R, Olson OC, Doroshow DB, Rohs NC, Gomez JE, Veluswamy R, Hall N, Venturini N, Ginhoux F, Liu Z, Buckup M, Figueiredo I, Roudko V, Miyake K, Karasuyama H, Gonzalez-Kozlova E, Gnjatic S, Passegué E, Kim-Schulze S, Brown BD, Hirsch FR, Kim BS, Marron TU, Merad M. LaMarche NM, et al. Nature. 2024 Jan;625(7993):166-174. doi: 10.1038/s41586-023-06797-9. Epub 2023 Dec 6. Nature. 2024. PMID: 38057662 Clinical Trial.
Myeloid cells are known to suppress antitumour immunity(1). However, the molecular drivers of immunosuppressive myeloid cell states are not well defined. Here we used single-cell RNA sequencing of human and mouse non-small cell lung cance …
Myeloid cells are known to suppress antitumour immunity(1). However, the molecular drivers of immunosuppressive myeloid cell states a …
Targeting KRAS in cancer.
Singhal A, Li BT, O'Reilly EM. Singhal A, et al. Nat Med. 2024 Apr;30(4):969-983. doi: 10.1038/s41591-024-02903-0. Epub 2024 Apr 18. Nat Med. 2024. PMID: 38637634 Review.
RAS family variants-most of which involve KRAS-are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small …
RAS family variants-most of which involve KRAS-are the most commonly occurring hotspot mutations in human cancers and are associated with a …
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Shaw AT, et al. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
We investigated the antitumour activity and safety of lorlatinib in advanced, ROS1-positive non-small-cell lung cancer (NSCLC). METHODS: In this open-label, single-arm, phase 1-2 trial, we enrolled patients (aged 18 years) with histologically or cytolo …
We investigated the antitumour activity and safety of lorlatinib in advanced, ROS1-positive non-small-cell lung …
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, Jabbour SK, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Schoenfeld JD, et al. Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.
BACKGROUND: Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. ...However, PD-L1 plus CTLA-4 therapy could be a treatment option for some patients. Future studies should r …
BACKGROUND: Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targe …
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer.
Zhao S, Zhuang W, Han B, Song Z, Guo W, Luo F, Wu L, Hu Y, Wang H, Dong X, Jiang D, Wang M, Miao L, Wang Q, Zhang J, Fu Z, Huang Y, Xu C, Hu L, Li L, Hu R, Yang Y, Li M, Yang X, Zhang L, Huang Y, Fang W. Zhao S, et al. Nat Commun. 2023 Jun 12;14(1):3468. doi: 10.1038/s41467-023-39139-4. Nat Commun. 2023. PMID: 37308490 Free PMC article. Clinical Trial.
EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. ...Subgroup analyses were performed by clinicopathological features and prior treatments. In …
EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited t …
Pembrolizumab-induced agranulocytosis.
Fernández Martínez V, García-Avello Fernández-Cueto A, Valencia Soto CM, Barbadillo Villanueva S, Ochagavía Sufrategui M, Rioja Carrera M, Alonso Buznego LA, Valero Domínguez M. Fernández Martínez V, et al. J Oncol Pharm Pract. 2024 Jun;30(4):767-771. doi: 10.1177/10781552241228774. Epub 2024 Jan 30. J Oncol Pharm Pract. 2024. PMID: 38291678
INTRODUCTION: With the widespread use of anti-programmed death-1 monoclonal antibodies, such as pembrolizumab, rare side effects appear in clinical practice. CASE REPORT: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stag …
INTRODUCTION: With the widespread use of anti-programmed death-1 monoclonal antibodies, such as pembrolizumab, rare side effects appear in c …
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Waqar SN, Redman MW, Arnold SM, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Stinchcombe TE, Leighl NB, Ramalingam SS, Tanna SH, Raddin RS, Minichiello K, Bradley JD, Kelly K, Herbst RS, Papadimitrakopoulou VA. Waqar SN, et al. Clin Lung Cancer. 2021 May;22(3):170-177. doi: 10.1016/j.cllc.2020.09.013. Epub 2020 Oct 14. Clin Lung Cancer. 2021. PMID: 33221175 Free PMC article. Clinical Trial.
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c-MET, in patients with c-MET-positive squamous cell carcinoma (SCC). PATIENTS AND METHODS: Patients with previously treated SCC …
INTRODUCTION: Lung-MAP S1400K was designed to evaluate the response to telisotuzumab vedotin, an antibody-drug conjugate targeting c- …
403 results